Inventiva S.A.
IVEVF
Get informed when a big investor buys or sells
+ FollowMarket Cap$185.06M
Close$
Share Statistics
| Market cap | $185.06 Million |
|---|---|
| Enterprise Value | $85.63 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -946.81% |
|---|---|
| Return on Assets | -222.38% |
| Return on Invested Capital | -234.76% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.94 |
| Enterprise Value to EBIT | -0.2 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.78 |
| Debt to Equity | 1.13 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Inventiva
77 employees
CEO: Frederic Cren Inventiva S.A. is a clinical-stage biopharmaceutical firm dedicated to developing oral small molecule therapies. Its primary therapeutic focus areas include non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various o...